(Q34094838)

31 July 2017

1 reference

title

Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1). (English)

1 reference

31 July 2017

0 references

1 reference

1 reference

G J Kontoghiorghes

1

1 reference

31 July 2017

K Pattichi

series ordinal

2

1 reference

31 July 2017

M Hadjigavriel

series ordinal

3

1 reference

31 July 2017

A Kolnagou

series ordinal

4

1 reference

31 July 2017

publication date

1 December 2000

1 reference

31 July 2017

1 reference

31 July 2017

volume

23

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

211-223

1 reference

Oxygen free radicals and iron in relation to biology and medicine: some problems and concepts

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Comparative study of iron mobilization from haemosiderin, ferritin and iron(III) precipitates by chelators

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

The study of iron mobilisation from transferrin using alpha-ketohydroxy heteroaromatic chelators

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Continuous subcutaenous administration of deferoxamine in patients with iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Iron chelation with oral desferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Desferrioxamine suppositories

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Evaluation of a new method of administration of the iron chelating agent deferoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Syntheses of iron bis(pyridoxal isonicotinoylhydrazone)s and the in vivo iron-removal properties of some pyridoxal derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Design, properties, and effective use of the oral chelator L1 and other alpha-ketohydroxypyridines in the treatment of transfusional iron overload in thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Selection of a new generation of orally active alpha-ketohydroxypyridine iron chelators intended for use in the treatment of iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

1,2-Dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Orally active alpha-ketohydroxypyridine iron chelators: effects on iron and other metal mobilisations

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

In Vitro Screening of Iron Chelators Using Models of Free Radical Damage

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Comparative efficacy and toxicity of desferrioxamine, deferiprone and other iron and aluminium chelating drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Prophylaxis of systemic yersinosis in thalassaemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis).

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

The effect of synthetic iron chelators on bacterial growth in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassaemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Oral iron chelation with L1

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Long-term trial with the oral iron chelator 1, 2-dimethyl-3-hydroxypyrid-4-one (L1). I. Iron chelation and metabolic studies

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

A multi-center safety trial of the oral iron chelator deferiprone.

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Oral iron chelation with deferiprone

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Effect of oral iron chelator L1 on iron absorption in man

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Salivary measurement of deferiprone concentrations and correlation with serum levels

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Long-term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Iron-chelation therapy with oral deferiprone--toxicity or lack of efficacy?

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Agranulocytosis and thrombocytopenia in patient with Blackfan-Diamond anaemia during oral chelator trial

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Idiosyncratic drug reactions: possible role of reactive metabolites generated by leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

Deferiprone for thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0955-3886%2800%2900089-8

7 January 2021

10.1016/S0955-3886(00)00089-8

Identifiers

DOI

1 reference

31 July 2017

1 reference